Thursday, October 22, 2026
The top medical stories of the day, as they ran.
Morning edition
14 stories
- 1FDA approves GSK and Ionis hepatitis B drug HibsagoDrugs and FDA · 5 outlets
- 2KFF finds employer family premiums rose 5% to $28,303 in 2026Insurance · 5 outlets
- 3Nigeria confirms imported Ebola case as outbreak spreads across countriesOutbreaks · 3 outlets
- 4Christina Applegate says her MS diagnosis was incorrectDiagnostics · 4 outlets
- 5Roivant reports brepocitinib success in two uveitis trialsDrugs and FDA · 3 outlets
- 6Pope Leo needs no further cancer treatment after lung surgeryCancer · 3 outlets
- 7Retatrutide improved sleep apnea in two trials of adults with obesityResearch · 3 outlets
- 8Guinea-Bissau hepatitis B newborn vaccine trial haltedVaccines · 2 outlets
- 9New multisociety guideline broadens dyslipidemia risk assessmentHeart health · 1 outlet
- 10Psilocybin linked to lower inflammation markers in small Parkinson’s studyResearch · 2 outlets
- 11NEJM publishes mixed findings from ianalumab trials in Sjögren’s diseaseResearch · 2 outlets
- 12Alcon acquires Neurotech Pharmaceuticals and its MacTel therapyIndustry · 2 outlets
- 13Carolina Infusion recalls 16 compounded medicines over sterility concernsDrug safety · 1 outlet
- 14Wedgewood recalls compounded veterinary medicines over potency concernsRecalls · 1 outlet
Evening edition
15 stories
- 1Moderna and Merck report melanoma vaccine cut recurrence or death risk by 42%Cancer · 4 outlets
- 2Employer health premiums rise 5%, while workers’ family contributions rise 9%Insurance · 6 outlets
- 3France reports first known human Shamonda virus infectionInfectious disease · 6 outlets
- 4FDA approves GSK and Ionis hepatitis B drug HibsagoDrugs and FDA · 3 outlets
- 5Commonwealth Fund finds uninsured rate rose to 11.2% in 2026Insurance · 2 outlets
- 6Calley Means resigns from Trump administration health advisory roleHealth policy · 4 outlets
- 7Pope Leo will not need further treatment after lung cancer surgeryCancer · 3 outlets
- 8FDA warns of counterfeit, contaminated eye drops sold in USDrug safety · 1 outlet
- 9FDA approves Ultomiris for proteinuria in primary IgA nephropathyDrugs and FDA · 2 outlets
- 10Roivant drug meets primary endpoint in two phase 3 uveitis trialsDrugs and FDA · 2 outlets
- 11AbbVie reports Phase 3 success for lutikizumab skin treatmentDrugs and FDA · 2 outlets
- 12Risant Health agrees to acquire Oklahoma nonprofit Integris HealthHospitals · 2 outlets
- 13UK trial will test diabetes and ADHD drugs in people with Alzheimer’sResearch · 2 outlets
- 14Psilocybin linked to lower inflammation markers in small Parkinson’s studyResearch · 2 outlets
- 15Redesign Health and ARC Global merge in $2B dealIndustry · 2 outlets